Denmark's Novo Nordisk has agreed to pay $70 million ... semaglutide in phase 3 in combination with drugs from Gilead, a long-acting FGF21 analogue in phase 2, and early-stage candidates partnered ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback